Preliminary analysis flags adverse-event reports while federal guidance emphasizes total caffeine intake.
By SPEAKIN’ OUT NEWS
Energy drinks and stimulant supplements are drawing fresh scrutiny after researchers found they appeared disproportionately in reports of serious heart problems, particularly among younger adults.
The preliminary analysis, released November 2 by the American Heart Association, examined 28,345 reports submitted to an FDA safety database between 2017 and 2025. Of those, 854 involved caffeine- or stimulant-containing products.
Researchers found higher reporting of cardiac arrest, heart attacks and abnormal heart rhythms compared with products without those ingredients. About 45% of reports linking stimulant products with cardiovascular events involved adults ages 18 to 34.
“Our findings support the case for more systematic safety monitoring of caffeine- and stimulant-containing products,” said study author Sai Samayamanthula of the University of Virginia School of Medicine.
The analysis cannot show how frequently these problems occur among all users or prove the products caused them. Reports are voluntary, and the findings remain preliminary until publication as a full peer-reviewed paper.
For consumers, the FDA emphasizes counting caffeine from every source, including coffee, tea, energy products and certain medicines. A workout supplement may add to an intake that already includes several caffeinated drinks.
The agency cites 400 milligrams daily as an amount not generally associated with negative effects for most adults. That is not a universal safety guarantee: medications, medical conditions and individual sensitivity can change how a person responds.
FDA guidance also notes that medical experts advise against energy drinks for children and teenagers. Excess caffeine can contribute to palpitations, anxiety and sleep problems.
Consumers can check labels for caffeine amounts and ask manufacturers when information is unclear. People concerned about a medicine, condition or caffeine sensitivity should discuss their intake with a healthcare professional.